News | January 21, 2026
Brenig Therapeutics launches first-in-human trial of novel neurodegenerative therapy
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
The trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination therapy
NTX-253 is a potent, selective, orally available positive allosteric modulator (PAM) of the muscarinic M4 receptor
_256_384.jpg){kind=logo}
Fasting glucose improved by 12.3 mg/dL, while liver stiffness dropped 23.7%, signaling a direct hepatic benefit
The accelerated review covers WCK 5222 for multiple critical infections
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
AVT03 is a biosimilar of Amgen's Prolia (denosumab 60 mg/mL) and Xgeva (denosumab 70 mg/mL), which are used to treat various bone conditions
The presentation will provide qualitative insights into its safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in patients with solid tumors
ABP-745 is a novel oral therapy with potential applications in cardiovascular and other inflammatory diseases
The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
Subscribe To Our Newsletter & Stay Updated
